Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era

Cancer medicine

Volumn 3, Issue 3, 2014, Pages 660-666

  Wachtel, Mitchell S ^a   Yang, Shengping ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; glioblastoma; odds of death; population database; SEER; temozolomide

Indexed keywords

BEVACIZUMAB; DACARBAZINE; MONOCLONAL ANTIBODY; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; UNITED STATES;

EID: 84921817672     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.213     Document Type: Article

References (0)